4K45

Auto-inhibition and phosphorylation-induced activation of PLC-gamma isozymes


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.5 Å
  • R-Value Free: 0.198 
  • R-Value Work: 0.173 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Autoinhibition and Phosphorylation-Induced Activation of Phospholipase C-gamma Isozymes.

Hajicek, N.Charpentier, T.H.Rush, J.R.Harden, T.K.Sondek, J.

(2013) Biochemistry 52: 4810-4819

  • DOI: 10.1021/bi400433b
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Multiple extracellular stimuli, such as growth factors and antigens, initiate signaling cascades through tyrosine phosphorylation and activation of phospholipase C-γ (PLC-γ) isozymes. Like most other PLCs, PLC-γ1 is basally autoinhibited by its X-Y l ...

    Multiple extracellular stimuli, such as growth factors and antigens, initiate signaling cascades through tyrosine phosphorylation and activation of phospholipase C-γ (PLC-γ) isozymes. Like most other PLCs, PLC-γ1 is basally autoinhibited by its X-Y linker, which separates the X- and Y-boxes of the catalytic core. The C-terminal SH2 (cSH2) domain within the X-Y linker is the critical determinant for autoinhibition of phospholipase activity. Release of autoinhibition requires an intramolecular interaction between the cSH2 domain and a phosphorylated tyrosine, Tyr783, also located within the X-Y linker. The molecular mechanisms that mediate autoinhibition and phosphorylation-induced activation have not been defined. Here, we describe structures of the cSH2 domain both alone and bound to a PLC-γ1 peptide encompassing phosphorylated Tyr783. The cSH2 domain remains largely unaltered by peptide engagement. Point mutations in the cSH2 domain located at the interface with the peptide were sufficient to constitutively activate PLC-γ1, suggesting that peptide engagement directly interferes with the capacity of the cSH2 domain to block the lipase active site. This idea is supported by mutations in a complementary surface of the catalytic core that also enhanced phospholipase activity.


    Organizational Affiliation

    Department of Pharmacology and ‡Department of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine , Chapel Hill, North Carolina 27599-7365, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1
A
106Rattus norvegicusMutation(s): 0 
Gene Names: Plcg1
EC: 3.1.4.11
Find proteins for P10686 (Rattus norvegicus)
Go to UniProtKB:  P10686
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, short peptide
B
18Rattus norvegicusMutation(s): 0 
Gene Names: Plcg1
EC: 3.1.4.11
Find proteins for P10686 (Rattus norvegicus)
Go to UniProtKB:  P10686
Small Molecules
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
B
L-PEPTIDE LINKINGC9 H12 N O6 PTYR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.5 Å
  • R-Value Free: 0.198 
  • R-Value Work: 0.173 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 29.013α = 90.00
b = 54.506β = 90.00
c = 59.865γ = 90.00
Software Package:
Software NamePurpose
DENZOdata reduction
PHASERphasing
SCALEPACKdata scaling
PHENIXrefinement
HKL-2000data collection

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2013-06-26
    Type: Initial release
  • Version 1.1: 2013-11-06
    Type: Database references
  • Version 1.2: 2014-01-22
    Type: Database references